Updates in the Treatment of Metastatic Urothelial Cancer

Systemic therapy options for advanced bladder cancer continue to expand.  The approvals of new therapies or combinations of therapies and emerging clinical trial data continue to impact the treatment landscape, and education on the topic would be valuable to help clinicians stay up to date with the latest research

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, PAs, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

  • Describe new and emerging systemic therapy options for patients with metastatic urothelial bladder cancer and how patient and disease characteristics can guide therapy choice.
  • Discuss the results of recent clinical trials for treatment of bladder cancer and their potential impact on treatment.
  • Review recent NCCN Guideline updates for the treatment of bladder cancer, and how they may be incorporated into clinical practice.

You may also be interested in

NCCN Guidelines® Insights - Bladder Cancer, Version 3.2024
These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.
Additional information
Supporters: 

Supported by educational grants from AstraZeneca; Coherus BioSciences; Dendreon Pharmaceuticals LLC; Eisai; Exact Sciences; Genentech, a member of the Roche Group; GRAIL, LLC; GSK; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; Menarini-Stemline; Novartis; Novocure; Olympus Corporation of the Americas; Sanofi; Sirtex; and Taiho Oncology, Inc. Supported by independent educational grants from Daiichi Sankyo; Incyte Corporation; and Merck & Co., Inc., Rahway, NJ, USA. Supported by independent medical education grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Regeneron Pharmaceuticals, Inc. Supported by a grant from Pfizer Inc. Supported by a medical education grant from Karyopharm Therapeutics. This project has been made possible in part by a grant from Varian Medical Systems, a Siemens Healthineers company/Global Medical Education Grant Program.

Course summary
Available credit: 
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation
Course opens: 
06/15/2024
Course expires: 
03/01/2025
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2024 Annual Conference

Thomas W. Flaig, MD
University of Colorado Cancer Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has no relevant financial relationships with ineligible companies to disclose.

Michael Serzan, MD

The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Thomas W. Flaig, MD 
Agensys, Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Aurora Oncology: Equity Interest/Stock Options; Intellectual Property Rights
Bristol Myers Squibb: Grant/Research Support
Criterium, Inc.: Consulting Fee; Scientific Advisor
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Merck & Co., Inc.: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support 
SeaGen: Grant/Research Support 

NCCN Staff Disclosures

The planner listed below has the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal Denlinger, MD, FACP 
2seventy bio: Grant/Research Support
AbbVie, Inc.: Grant/Research Support
Bluebird bio: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc: Grant/Research Support
GSK: Grant/Research Support
Pfizer Inc: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour, 0.75 of which are pharmacotherapeutic contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit. UAN: JA4008196-0000-24-070-H01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit. Approval is valid until March 1, 2025. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
    • 0.75 ANCC Pharmacology Contact Hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing